ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ,
Irena KRONTORÁD KOUTNÁ,
Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and
Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Leukemia & lymphoma. England: Informa Healthcare, 2012, vol. 53, No 8, p. 1627-1629. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104.